Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMyeloma 2015 | Emerging monoclonal antibodies for the treatment of multiple myeloma

Rafael Fonseca • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma Antibodies Elotuzumab

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses novel monoclonal antibodies (mAbs) for the treatment of multiple myeloma. Anti-CD38 mAbs and elotuzumab are showing promising activity in clinical development.

More from Rafael Fonseca

The eMMpower Consortium: real-world data to understand the characteristics and patterns of myeloma
1:01
The eMMpower Consortium: real-world data to understand the characteristics and patterns of myeloma
Rafael Fonseca • 20 Sep 2025
Cilta-cel versus conventional treatment regimens in multiple myeloma: a real-world study
1:11
Cilta-cel versus conventional treatment regimens in multiple myeloma: a real-world study
Rafael Fonseca • 20 Sep 2025
Circulating tumor DNA assessment in multiple myeloma: emerging evidence for clinical utility
1:50
Circulating tumor DNA assessment in multiple myeloma: emerging evidence for clinical utility
Rafael Fonseca • 20 Sep 2025
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
14:14
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
Rafael Fonseca • 12 Apr 2025

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Rafael Fonseca • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Rafael Fonseca • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Rafael Fonseca • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Rafael Fonseca • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals